4.22
+1.69%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Artiva Biotherapeutics
From its filings with the US Securities and Exchange Commission
Artiva Biotherapeutics is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ARTV. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $83.9m. At that date it held total assets of $130.9m and shareholders' equity of $110.0m.
We are a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patient’s own cells (autologous) and are pre-manufactured and stored frozen and ready to ship to a patient’s treatment location, making them what we believe to be “off-the-shelf.” Our lead product candidate, AlloNK (also known as AB-101), is an allogeneic, non-genetically modified, cryopreserved NK cell therapy designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of monoclonal antibodies (mAbs) to drive B-cell depletion. We are currently evaluating AlloNK in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases, including a company-sponsored basket trial across autoimmune diseases that includes rheumatoid arthritis (RA) and Sjögren’s disease (SjD). We are prioritizing refractory RA as our lead indication for AlloNK development. We expect to share initial clinical response data across dose levels from more than 15 refractory RA patients, several of whom will have 6 months or more follow up, in the first half of 2026. In addition, we plan to conduct FDA regulatory interactions in the first half of 2026 to align on the pivotal trial design for AlloNK in refractory RA.
Quoted from its 10-K, filed 10 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 19 Jul 2024
- Employees
- 81
- Website
- artivabio.com ↗
- Head office
- 5505 MOREHOUSE DRIVE, SAN DIEGO, CA, 92121
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Dr. Brian DanielsIndependent Chairman of the Board$42,741
- Dr. Fred AslanPresident, Chief Executive Officer, Director, since 2021$7.8m
- Ms. Neha KrishnamohanChief Financial Officer, Executive Vice President - Corporate Development$2.2m
- Mr. Christopher HoranChief Technical Operations Officer$726,895
- Ms. Jennifer BushChief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer$1.5m
- Dr. Heather RaymonSenior Vice President - Research and Early Development
- Dr. Subhashis BanerjeeChief Medical Officer
- Dr. Diego MirallesDirector$278,968
- Ms. Elizabeth HougenIndependent Director$87,300
- Dr. Alison MooreIndependent Director$227,817
- Dr. Laura StoppelIndependent Director$22,614
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- AlloNK is a non-genetically modified, cryopreserved NK cell therapy ready for immediate use in patients.
- The company focuses on clinical-stage biotechnology with a lead product candidate in Phase I/Ib trials for autoimmune diseases and cancers.
- Artiva Biotherapeutics employs 81 full-time employees with a headquarters in San Diego, California.
Weaknesses
- The company's lead product candidate AlloNK is still in Phase I/Ib trials with no commercial approval yet.
- Artiva Biotherapeutics has only one product candidate, AlloNK, in clinical development.
- The company's IPO occurred on 19 July 2024, indicating early-stage financial development.
Opportunities
- AlloNK is being evaluated in combination with B-cell targeted mAbs for autoimmune diseases like lupus nephritis and SLE.
- The basket investigator-initiated trial (IIT) in multiple autoimmune indications offers potential expansion for AlloNK.
- Artiva Biotherapeutics' focus on allogeneic NK cell therapies could address unmet needs in cancer and autoimmune treatment.
Threats
- The clinical trials for AlloNK face potential delays or failures in achieving regulatory approval.
- The biotechnology industry is highly competitive with many established players in NK cell therapies.
- Regulatory hurdles for new biologic therapies could slow down the commercialization of AlloNK.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.